✔︎ 5 Memorial Day mattress-in-a-box deals: Save up to 60%
Memorial Day weekend is one of the best times of the year to buy a new mattress, and 2025's deals are bigger than ever. Whether you're furnishing a new bedroom or giving a guest room a well-needed upgrade, we've rounded up the top five Memorial Day mattress-in-a-box deals at some of the most popular brands. With deep discounts on comfortable sleepers, free bedding bundles and extended trials, what's not to love?
From plush memory foam to hybrid support, these deals deliver serious value and comfort. The best part about buying a mattress-in-a-box is that it arrives compressed in a compact box (or a bag, in Purple's case)—no need to coordinate with movers or delivery crews. Just unbox, unroll and let it expand!
Shop the best MDW sales at mattress brands like Casper, Purple, Leesa and more.
Top 5 Memorial Day 2025 mattress-in-a-box deals
Here are the best mattress-in-a-box deals for Memorial Day, based on current sales at top-rated mattress brands:
1. Casper Snow Mattress, Queen
2. DreamCloud Premier Hybrid Mattress, Queen
Memorial Day military discount: Extra 5% off any DreamCloud order
More: Get a DreamCloud mattress for $649 at this Memorial Day sale ⏰
3. Leesa Legend Hybrid Mattress, Queen
Sleep soundly this Memorial Day: Get up to $1,110 off Leesa mattresses
More: Get up to $799 off a new Purple mattress at this Memorial Day sale
5. Nectar Premier Memory Foam Mattress, Queen
More: Nectar hybrid and memory foam mattresses are up to 50% off at this huge Memorial Day sale
Are these mattresses easy to set up?
Yes! Mattress-in-a-box models arrive compressed and expand within hours of unboxing.
More: Parachute's dreamiest bedding sets, bath robes are 30% off at this Memorial Day sale
Are Memorial Day mattress deals better than other holiday sales?
Yes, Memorial Day is one of the best times of year to buy a mattress, often rivaling Black Friday and Labor Day in terms of discounts and special bundle offers.
When do Memorial Day mattress sales start and end?
Most mattress sales begin in early to mid-May and run through Memorial Day on Monday, May 26. Some brands extend deals into early June.
Memorial Day 2025 shopping guide: Best sales, deals, where to shop now
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 days ago
- Business Insider
The most comfortable memory foam bed we've ever tested is on sale — save 30% on the Tempur-Pedic Cloud Mattress
Tempur-Pedic is one of the most luxurious and innovative mattress brands on the market, and it has the high price tags to match, with some mattresses going for over $10,000 on the site. Luckily, our favorite Tempur-Pedic bed also happens to be its most affordable, the Cloud Mattress. Plus, you can save even more on it right now with the current Tempur-Pedic Cloud Mattress deal. The Tempur-Pedic Cloud Mattress features contouring foam that cradles sleepers of all body types and sleeping styles while offering outstanding pressure relief and heat dissipation. Note: The price shown here is for the queen-sized mattress, but the discount also applies to some other sizes, which are selectable on the same its usual price of just under $2,000, we already think the Cloud Mattress is a good deal for its quality. But while the current deal lasts, you can save an extra $600 on the bed. It's common to score up to $300 worth of free bedding and accessories at Tempur-Pedic, but mattress discounts are much harder to come by outside major holidays, so you won't want to sleep on this first bed-in-a-box features the same proprietary Tempur-Material foam we've come to know and love from the brand. It molds perfectly to the contours of your body for top-notch pressure relief, making it the best memory foam mattress we've ever bed's medium firmness makes it a great choice for all sleep types, landing it in several of our mattress guides, including the best for back pain, best for side sleepers, and more. While foam mattresses are often known for trapping warmth, the Cloud Mattress also excels at heat dissipation, and even made it into our best cooling mattress guide. Its only flaw is its less-than-ideal edge support, which could be challenging for our full Tempur-Pedic Cloud Mattress review to learn more about how we tested. Plus, check out our Tempur-Pedic review to see all the beds we've tried from the the current discount, the queen-size Tempur-Pedic Cloud Mattress is 30% off. Add it to your cart now for just $1,399.30 while the deal mattress sales | Twin and twin XL mattress sales | Casper coupons | Big Fig promo codes | Mattress Firm discount codes | Purple mattress couponsThe Tempur-Pedic Cloud Mattress comes with a 10-year full replacement limited warranty. Learn more about what the warranty covers on Tempur-Pedic's Tempur-Pedic Cloud Mattress deal will end on Monday, July 28, so be sure to place your order this us on Instagram and WhatsApp to keep up with the latest deals, reviews, and buying guides.
Yahoo
4 days ago
- Yahoo
TMO Q2 Deep Dive: Pharma Strength, Tariff Adaptation, and Strategic Investments Shape Outlook
Life sciences company Thermo Fisher (NYSE:TMO) reported Q2 CY2025 results beating Wall Street's revenue expectations , with sales up 3% year on year to $10.86 billion. Its non-GAAP profit of $5.36 per share was 2.5% above analysts' consensus estimates. Is now the time to buy TMO? Find out in our full research report (it's free). Thermo Fisher (TMO) Q2 CY2025 Highlights: Revenue: $10.86 billion vs analyst estimates of $10.69 billion (3% year-on-year growth, 1.6% beat) Adjusted EPS: $5.36 vs analyst estimates of $5.23 (2.5% beat) Adjusted EBITDA: $2.61 billion vs analyst estimates of $2.59 billion (24.1% margin, 0.9% beat) Operating Margin: 16.9%, in line with the same quarter last year Organic Revenue rose 2% year on year (-1% in the same quarter last year) Market Capitalization: $176.2 billion StockStory's Take Thermo Fisher's second quarter saw a positive market response, as the company surpassed Wall Street's revenue and adjusted profit expectations. Management attributed the quarter's performance to robust growth in pharma and biotech, especially in bioproduction and Pharma Services, alongside strong execution in their research and safety market channel. CEO Marc Casper emphasized that 'customer uptake is very strong' for the company's Accelerator Drug Development solution, and highlighted sequential improvement in clinical research. However, Casper also noted mid-single-digit declines in academic and government markets, and low single-digit declines in diagnostics and health care, reflecting ongoing hesitancy and demand headwinds in these segments. Looking forward, Thermo Fisher's updated guidance reflects an expectation of gradual improvement in key end markets and ongoing margin expansion through cost management and innovation. Management highlighted strategic priorities such as expanding U.S. manufacturing capacity, integrating Solventum's Purification & Filtration business, and leveraging AI within their PPI Business System to enhance productivity. CFO Stephen Williamson noted, 'We're actively managing the company to appropriately navigate the macro environment,' while Casper outlined a scenario of accelerating growth in 2026 and 2027, anticipating organic revenue growth rising from current levels as academic and government headwinds abate and clinical research builds momentum. Key Insights from Management's Remarks Management attributed the quarter's outperformance to strong pharma and biotech demand, successful cost actions, and resilience in the face of tariffs, while also discussing product innovation and portfolio expansion. Pharma and Biotech Momentum: The company reported mid-single-digit growth in its pharma and biotech end markets, with bioproduction and Pharma Services driving results. Management cited strong customer interest in Accelerator Drug Development, which integrates Pharma Services and clinical research capabilities to reduce drug development time and cost. Academic and Government Weakness: Revenue from academic and government customers declined mid-single digits, with CEO Marc Casper pointing to muted demand and customer caution amid funding uncertainties. Casper indicated this segment is expected to stabilize over time but remains a headwind for now. Tariff Adaptation: Tariffs and related foreign exchange posed a significant headwind, impacting adjusted operating income and margins. Management minimized the impact through operational adjustments and active management, noting that tariff exposure was less severe than previously assumed, particularly in China. Product Innovation and Launches: Thermo Fisher introduced new mass spectrometry and electron microscopy products, including the Astral Zoom and Excedion Pro spectrometers and the Krios 5 cryo-transmission electron microscope. Customer feedback highlighted the potential of these tools to advance precision medicine and biological research. Portfolio and Capacity Expansion: The company amended its acquisition agreement with Solventum to accelerate regulatory clearance and exclude non-synergistic lines, while also announcing an expanded partnership with Sanofi through the acquisition of a sterile fill-finish facility in New Jersey. Management expects these moves to broaden manufacturing capabilities and support customer reshoring efforts. Drivers of Future Performance Thermo Fisher's outlook centers on cost discipline, new product adoption, and recovery in challenged end markets, with ongoing tariff and policy risks. Cost Management and Margin Expansion: Management expects continued productivity gains and cost reductions, leveraging the PPI Business System and AI integration. CFO Stephen Williamson outlined expectations for 50 to 70 basis points of adjusted operating margin expansion annually, even in a muted revenue environment. Recovery in Key Markets: Leadership anticipates that academic and government demand will transition from a headwind to stabilization, while clinical research and pharma services are expected to see improved growth as authorizations and customer activity increase. China remains a near-term headwind but is projected to flatten out over the next two years. Strategic Capital Deployment: The company plans to supplement organic performance with targeted acquisitions and capacity investments, particularly in U.S. manufacturing. The pending Solventum and Sanofi deals are expected to enhance product offerings and meet growing demand for domestic drug production, supporting long-term revenue and profit growth. Catalysts in Upcoming Quarters In the quarters ahead, our analyst team will closely watch (1) the pace of recovery in academic and government demand and whether stabilization emerges, (2) the successful integration and performance of Solventum's Purification & Filtration business and the Sanofi fill-finish facility, and (3) ongoing traction for new analytical instruments and bioproduction solutions. Execution on cost discipline and navigating tariff dynamics will also be key signposts for monitoring Thermo Fisher's ability to deliver on its outlook. Thermo Fisher currently trades at $467.60, up from $426.83 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it's free). Stocks That Trumped Tariffs When Trump unveiled his aggressive tariff plan in April 2024, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that's already erased most losses. Don't let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
5 days ago
- Yahoo
Why Thermo Fischer Stock Is Rising Wednesday
Thermo Fisher Scientific Inc. (NYSE:TMO) on Wednesday reported second-quarter 2025 adjusted earnings of $5.36 per share, beating the street view of $5.23. Quarterly sales of $10.86 billion increased 3% year-over-year, beating the analyst consensus estimate of $10.68 billion. Organic revenue growth was 2%. 'The agility of our organization, powered by the PPI Business System, allowed us to effectively adapt to current market conditions, actively manage our cost base and deliver strong operational results in the second quarter,' said Marc Casper, chairman, president and CEO of Thermo Fisher Scientific. The company said, 'PPI is helping us adjust our supply chains in the tariff environment and to actively manage our cost base.' Also Read: Management Change: Thermo Fisher Scientific announced Stephen Williamson, senior vice president and CFO, has decided to retire from the company, effective March 31, 2026. The company's board of directors appointed Jim Meyer, vice president of financial operations, to succeed Williamson as CFO, effective March 1, 2026. Guidance: During an earnings conference call, Thermo Fisher Scientific forecasts 2025 revenue of $43.6 billion-$44.2 billion, compared to prior guidance of $43.3 billion-$44.2 billion and the consensus of $43.71 billion. View more earnings on TMO The company expects adjusted earnings of $22.22-$22.84 per share, compared to prior guidance of $21.76-$22.84 and consensus of $22.33. The company adds that the U.S.-China tariff situation has improved significantly compared to prior assumptions. Last week, Thermo Fisher Scientific announced an expansion of its strategic partnership with Sanofi SA (NASDAQ:SNY) to enable additional U.S. drug product manufacturing. The terms of the deal were not disclosed. Under the agreement, Thermo Fisher will acquire Sanofi's steriles manufacturing site in Ridgefield, New Jersey, and continue to manufacture a portfolio of therapies for Sanofi. In addition, Thermo Fisher will expand use of the site to meet the growing demand from pharma and biotech customers for U.S. manufacturing capacity. The Ridgefield site is a sterile fill-finish and packaging facility with over 200 employees who will join Thermo Fisher following the completion of the transaction. The transaction is expected to be completed in the second half of 2025. Upon completion of the transaction, Sanofi's Ridgefield facility will become part of Thermo Fisher's pharma services business within its Laboratory Products and Biopharma Services segment. Price Action: TMO stock is up 13.2% at $483.94 at the last check on Wednesday. Read Next:Photo: Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? THERMO FISHER SCIENTIFIC (TMO): Free Stock Analysis Report This article Why Thermo Fischer Stock Is Rising Wednesday originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
